{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:21:37Z","timestamp":1786486897241,"version":"build-2736575974"},"reference-count":331,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["AGL2016-79813-C2-1R"],"award-info":[{"award-number":["AGL2016-79813-C2-1R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["SAF2017-83575-R"],"award-info":[{"award-number":["SAF2017-83575-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["RYC-2015-18368"],"award-info":[{"award-number":["RYC-2015-18368"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008431","name":"Consejer\u00eda de Educaci\u00f3n, Junta de Castilla y Le\u00f3n","doi-asserted-by":"publisher","award":["LE020P17"],"award-info":[{"award-number":["LE020P17"]}],"id":[{"id":"10.13039\/501100008431","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Marine Drugs"],"abstract":"<jats:p>Neglected Tropical Diseases (NTD) represent a serious threat to humans, especially for those living in poor or developing countries. Almost one-sixth of the world population is at risk of suffering from these diseases and many thousands die because of NTDs, to which we should add the sanitary, labor and social issues that hinder the economic development of these countries. Protozoan-borne diseases are responsible for more than one million deaths every year. Visceral leishmaniasis, Chagas disease or sleeping sickness are among the most lethal NTDs. Despite not being considered an NTD by the World Health Organization (WHO), malaria must be added to this sinister group. Malaria, caused by the apicomplexan parasite Plasmodium falciparum, is responsible for thousands of deaths each year. The treatment of this disease has been losing effectiveness year after year. Many of the medicines currently in use are obsolete due to their gradual loss of efficacy, their intrinsic toxicity and the emergence of drug resistance or a lack of adherence to treatment. Therefore, there is an urgent and global need for new drugs. Despite this, the scant interest shown by most of the stakeholders involved in the pharmaceutical industry makes our present therapeutic arsenal scarce, and until recently, the search for new drugs has not been seriously addressed. The sources of new drugs for these and other pathologies include natural products, synthetic molecules or repurposing drugs. The most frequent sources of natural products are microorganisms, e.g., bacteria, fungi, yeasts, algae and plants, which are able to synthesize many drugs that are currently in use (e.g. antimicrobials, antitumor, immunosuppressants, etc.). The marine environment is another well-established source of bioactive natural products, with recent applications against parasites, bacteria and other pathogens which affect humans and animals. Drug discovery techniques have rapidly advanced since the beginning of the millennium. The combination of novel techniques that include the genetic modification of pathogens, bioimaging and robotics has given rise to the standardization of High-Performance Screening platforms in the discovery of drugs. These advancements have accelerated the discovery of new chemical entities with antiparasitic effects. This review presents critical updates regarding the use of High-Throughput Screening (HTS) in the discovery of drugs for NTDs transmitted by protozoa, including malaria, and its application in the discovery of new drugs of marine origin.<\/jats:p>","DOI":"10.3390\/md18040187","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T03:44:13Z","timestamp":1585712653000},"page":"187","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Screening Marine Natural Products for New Drug Leads against Trypanosomatids and Malaria"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0930-0371","authenticated-orcid":false,"given":"Mar\u00eda","family":"\u00c1lvarez-Bard\u00f3n","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences; University of Le\u00f3n, 24071 Le\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"P\u00e9rez-Pertejo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences; University of Le\u00f3n, 24071 Le\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Ord\u00f3\u00f1ez","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences; University of Le\u00f3n, 24071 Le\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8053-6045","authenticated-orcid":false,"given":"Daniel","family":"Sep\u00falveda-Crespo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences; University of Le\u00f3n, 24071 Le\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nestor M.","family":"Carballeira","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Puerto Rico, R\u00edo Piedras 00925-2537, San Juan, Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babu L.","family":"Tekwani","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Division of Drug Discovery, Southern Research, Birmingham, AL 35205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankaranarayanan","family":"Murugesan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Birla Institute of Technology and Science, Pilani Campus, Vidya Vihar, Pilani 333031, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3723-1895","authenticated-orcid":false,"given":"Maria","family":"Martinez-Valladares","sequence":"additional","affiliation":[{"name":"Department of Animal Health, Instituto de Ganader\u00eda de Monta\u00f1a (CSIC-Universidad de Le\u00f3n), Grulleros, 24346 Le\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Garc\u00eda-Estrada","sequence":"additional","affiliation":[{"name":"INBIOTEC (Instituto de Biotecnolog\u00eda de Le\u00f3n), Avda. Real 1-Parque Cient\u00edfico de Le\u00f3n, 24006 Le\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa M.","family":"Reguera","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences; University of Le\u00f3n, 24071 Le\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0418-6116","authenticated-orcid":false,"given":"Rafael","family":"Bala\u00f1a-Fouce","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences; University of Le\u00f3n, 24071 Le\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.4062\/biomolther.2016.181","article-title":"Marine-derived pharmaceuticals\u2014Challenges and opportunities","volume":"24","author":"Lindequist","year":"2016","journal-title":"Biomol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Fusetani, N. (2000). Symbiotic bacteria in sponges: Sources of bioactive substances. Drugs from the Sea, Karger.","DOI":"10.1159\/isbn.978-3-318-00599-8"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1039\/C5NP00156K","article-title":"Marine natural products","volume":"33","author":"Blunt","year":"2016","journal-title":"Nat. Prod. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pereira, R.B., Evdokimov, N.M., Lefranc, F., Valent\u00e3o, P., Kornienko, A., Pereira, D.M., Andrade, P.B., and Gomes, N.G.M. (2019). Marine-derived anticancer agents: Clinical benefits, innovative mechanisms, and new targets. Mar. Drugs, 17.","DOI":"10.3390\/md17060329"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40265-017-0705-5","article-title":"Brentuximab Vedotin: A review in CD30-positive Hodgkin lymphoma","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1517\/14656566.2016.1146683","article-title":"Review on the clinical use of eribulin mesylate for the treatment of breast cancer","volume":"17","author":"Aseyev","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open\u2013label, multicentre, phase 3 trial","volume":"387","author":"Chawla","year":"2016","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1021\/jo00302a007","article-title":"Ecteinascidins 729, 743, 745, 759A, 759B, and 770: Potent antitumour agents from the Caribbean tunicate Ecteinascidia turbinata","volume":"55","author":"Rinerhart","year":"1990","journal-title":"J. Org. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: Results of a phase III randomized multicenter clinical trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1470-2045(00)00292-8","article-title":"Marine organisms as a source of new anticancer agents","volume":"2","author":"Schwartsmann","year":"2001","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(16)30171-4","article-title":"Neglected tropical diseases: Progress towards addressing the chronic pandemic","volume":"389","author":"Molyneux","year":"2017","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mitra, A.K., and Mawson, A.R. (2017). Neglected tropical diseases: Epidemiology and global burden. Trop. Med. Infect. Dis., 2.","DOI":"10.3390\/tropicalmed2030036"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"P1113","DOI":"10.1016\/S1473-3099(16)30328-0","article-title":"Global burden on neglected tropical diseases","volume":"16","author":"Qian","year":"2016","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(13)60024-0","article-title":"Malaria","volume":"383","author":"White","year":"2014","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40249-019-0550-8","article-title":"The 2017 Oslo conference report on neglected tropical diseases and emerging\/re-emerging infectious diseases\u2014Focus on populations underserved","volume":"8","author":"Klohe","year":"2019","journal-title":"Infect. Dis. Poverty"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/S0140-6736(17)31510-6","article-title":"Human African trypanosomiasis","volume":"390","author":"Cecchi","year":"2017","journal-title":"Lancet"},{"key":"ref_18","unstructured":"Dunn, N., Wang, S., and Adigun, R. (2019). African Trypanosomiasis (Sleeping Sickness), StatPearls Publishing."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.idc.2018.10.003","article-title":"Human African Trypanosomiasis: Progress and stagnation","volume":"3","author":"Bottieau","year":"2019","journal-title":"Infect. Dis. Clin. North Am."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Franco, J.R., Cecchi, G., Priotto, G., Paone, M., Diarra, A., Grout, L., Simarro, P.P., Zhao, W., and Argaw, D. (2018). Monitoring the elimination of human African trypanosomiasis: Update to 2016. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006890"},{"key":"ref_21","unstructured":"World Health Organization (2019, December 01). Control and Surveillance of Human African Trypanosomiasis: Report of a WHO Expert Committee (World Health Organization). Available online: http:\/\/www.who.int\/iris\/handle\/10665\/95732."},{"key":"ref_22","unstructured":"GBD 2015 DALYs and HALE Collaborators (2016). Global, Regional, and National Disability-Adjusted Life-Years (DALYs) for 315 Diseases and Injuries and Healthy Life Expectancy (HALE), 1990\u20132015: A Systematic Analysis for the Global Burden of Disease Study 2015. Lancet, 388, 1603\u20131658."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Checchi, F., Filipe, J.A., Barrett, M.P., and Chandramohan, D. (2008). The natural progression of Gambiense sleeping sickness: What is the evidence?. PLoS Negl. Trop. Dis., 2.","DOI":"10.1371\/journal.pntd.0000303"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S1474-4422(12)70296-X","article-title":"Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)","volume":"12","author":"Kennedy","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Jamonneau, V., Ilboudo, H., Kabor\u00e9, J., Kaba, D., Koffi, M., Solano, P., Garcia, A., Courtin, D., Laveissi\u00e8re, C., and Lingue, K. (2012). Untreated human infections by Trypanosoma brucei gambiense are not 100% fatal. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001691"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(17)31612-4","article-title":"Chagas disease","volume":"391","author":"Molina","year":"2018","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.idc.2018.10.015","article-title":"American Trypanosomiasis (Chagas Disease)","volume":"33","author":"Echeverria","year":"2019","journal-title":"Infect. Dis. Clin. North Am."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1056\/NEJMra1410150","article-title":"Chagas\u2019 Disease","volume":"373","author":"Bern","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4269\/ajtmh.19-0310","article-title":"Chagas disease infection prevalence and vector exposure in a high-risk population of Texas hunters","volume":"102","author":"Gunter","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cmi.2017.04.013","article-title":"Challenges in the management of Chagas disease in Latin-American migrants in Europe","volume":"23","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10741-010-9211-5","article-title":"Chronic Chagas\u2019 heart disease: A disease on its way to becoming a worldwide health problem: Epidemiology, etiopathology, treatment, pathogenesis and laboratory medicine","volume":"17","author":"Haberland","year":"2012","journal-title":"Heart Fail. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00418-014-1250-x","article-title":"Chagasic megacolon: Enteric neurons and related structures","volume":"142","author":"Jabari","year":"2014","journal-title":"Histochem. Cell. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.ejim.2017.09.022","article-title":"Chagas disease in Europe: A long way to go","volume":"48","author":"Antinori","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"ref_34","first-page":"540","article-title":"Chagas disease and transfusion medicine: A perspective from non-endemic countries","volume":"13","author":"Angheben","year":"2015","journal-title":"Blood Transfus."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1111\/ajt.12340","article-title":"Donor-derived Trypanosoma cruzi infection in solid organ recipients in the United States, 2001\u20132011","volume":"13","author":"Huprikar","year":"2013","journal-title":"Am. J. Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1590\/0074-02760140405","article-title":"Congenital Chagas disease: An update","volume":"110","author":"Carlier","year":"2015","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"750","DOI":"10.12688\/f1000research.11120.1","article-title":"Leishmaniasis: A review","volume":"6","author":"Esmenjaud","year":"2017","journal-title":"F1000Res"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0035-9203(02)90044-1","article-title":"Mechanisms of pathogenesis: Differences amongst Leishmania species","volume":"96","author":"Colmenares","year":"2002","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(07)70209-8","article-title":"Cutaneous leishmaniasis","volume":"7","author":"Reithinger","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jaad.2014.08.051","article-title":"Cutaneous and mucocutaneous leishmaniasis: Clinical perspectives","volume":"73","author":"Handler","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.idc.2012.03.005","article-title":"Visceral leishmaniasis","volume":"26","author":"Diro","year":"2012","journal-title":"Infect. Dis. Clin. North Am."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1473-3099(03)00517-6","article-title":"Post-kala-azar dermal leishmaniasis","volume":"3","author":"Zijlstra","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Alvar, J., Velez, I.D., Bern, C., Herrero, M., Desjeux, P., Cano, J., Jannin, J., and den Boer, M. (2012). WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035671"},{"key":"ref_45","unstructured":"World Health Organization (2019, January 09). Leishmaniasis. Geneva: World Health Organization. Available online: http:\/\/www.who.int\/mediacentre\/factsheets\/fs375\/en\/."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1016\/S1473-3099(16)30140-2","article-title":"Elimination of visceral leishmaniasis on the Indian subcontinent","volume":"16","author":"Singh","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1017\/S0031182016002031","article-title":"Evaluating drug resistance in visceral leishmaniasis: The challenges","volume":"145","author":"Hendrickx","year":"2018","journal-title":"Parasitology"},{"key":"ref_48","unstructured":"World Health Organization (2019, December 11). World Malaria Report. Available online: http:\/\/www.who.int\/malaria\/publications\/world_malaria_report_2012\/wmr2012_full_report.pdf."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0140-6736(19)31139-0","article-title":"Malaria eradication within a generation: Ambitious, achievable, and necessary","volume":"394","author":"Feachem","year":"2019","journal-title":"Lancet"},{"key":"ref_50","unstructured":"African Leaders Malaria Alliance (2018, September 17). About ALMA. Available online: http:\/\/alma2030.org\/about."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"105173","DOI":"10.1016\/j.actatropica.2019.105173","article-title":"An overview of leishmanization experience: A successful control measure and a tool to evaluate candidate vaccines","volume":"200","author":"Mohebali","year":"2019","journal-title":"Acta Trop."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.vetpar.2016.07.011","article-title":"Current status on prevention and treatment of canine leishmaniasis","volume":"227","author":"Reguera","year":"2016","journal-title":"Vet. Parasitol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1080\/14760584.2016.1236689","article-title":"The RTS,S\/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination","volume":"15","author":"Vandoolaeghe","year":"2016","journal-title":"Expert Rev. Vaccin."},{"key":"ref_54","first-page":"1","article-title":"RTS,S\/AS01 vaccine (Mosquirix\u2122): An overview","volume":"22","author":"Laurens","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"11131","DOI":"10.1021\/cr500546h","article-title":"Introduction: Drug discovery and development for neglected diseases","volume":"114","author":"Goupil","year":"2014","journal-title":"Chem. Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"11138","DOI":"10.1021\/cr500098f","article-title":"Recent approaches to chemical discovery and development against malaria and the neglected tropical diseases human African trypanosomiasis and schistosomiasis","volume":"114","author":"Njoroge","year":"2014","journal-title":"Chem. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"C157","DOI":"10.12968\/hmed.2016.77.10.C157","article-title":"African sleeping sickness","volume":"77","author":"Hedley","year":"2016","journal-title":"Br. J. Hosp. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4269\/ajtmh.1996.55.586","article-title":"The efficacy of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis","volume":"55","author":"Doua","year":"1996","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jneuroim.2003.08.033","article-title":"Neuro-inflammatory risk factors for treatment failure in \u201cearly second stage\u201d sleeping sickness patients treated with pentamidine","volume":"144","author":"Lejon","year":"2003","journal-title":"J. Neuroimmunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6828","DOI":"10.1128\/AAC.01129-16","article-title":"Antileishmanial mechanism of diamidines involves targeting kinetoplasts","volume":"60","author":"Yang","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molbiopara.2006.11.013","article-title":"S-Adenosyl-methionine in protozoan parasites: Functions, synthesis and regulation","volume":"152","author":"Reguera","year":"2007","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Song, J., Baker, N., Rothert, M., Henke, B., Jeacock, L., Horn, D., and Beitz, E. (2016). Pentamidine is not a permeant but a nanomolar inhibitor of the Trypanosoma brucei aquaglyceroporin-2. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005436"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Lutje, V., Seixas, J., and Kennedy, A. (2013). Chemotherapy for second-stage Human African trypanosomiasis. Cochrane Database Syst. Rev., D006201.","DOI":"10.1002\/14651858.CD006201.pub3"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.bjp.0707354","article-title":"Human African trypanosomiasis: Pharmacological re-engagement with a neglected disease","volume":"152","author":"Barrett","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1017\/S0031182010001137","article-title":"Chemotherapy against human African trypanosomiasis: Is there a road to success?","volume":"137","author":"Burri","year":"2010","journal-title":"Parasitology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/j.1552-4604.1986.tb02897.x","article-title":"Clinical pharmacokinetics of suramin in patients with HTLV-III\/LAV infection","volume":"26","author":"Collins","year":"1986","journal-title":"J. Clin. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jnr.490210109","article-title":"Spread of Trypanosoma brucei to the nervous system: Early attack on circumventricular organs and sensory ganglia","volume":"21","author":"Schultzberg","year":"1988","journal-title":"J. Neurosci. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0166-6851(02)00096-8","article-title":"Evidence for a non-LDL-mediated entry route for the trypanocidal drug suramin in Trypanosoma brucei","volume":"122","author":"Pal","year":"2002","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/j.1460-2075.1987.tb04741.x","article-title":"Common elements on the surface of glycolytic enzymes from Trypanosoma brucei may serve as topogenic signals for import into glycosomes","volume":"6","author":"Wierenga","year":"1987","journal-title":"EMBO J."},{"key":"ref_70","unstructured":"Cook, G., and Zumla, A. (2008). Human African trypanosomiasis. Manson\u2019s Tropical Diseases, Saunders. Chapter 76."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1086\/429929","article-title":"Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: Confirmation from a multinational study (IMPAMEL II)","volume":"191","author":"Schmid","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.pt.2018.04.002","article-title":"Melarsoprol resistance in African Trypanosomiasis","volume":"34","author":"Fairlamb","year":"2018","journal-title":"Trends Parasitol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1073\/pnas.86.8.2607","article-title":"Trypanothione is the primary target for arsenical drugs against African trypanosomes","volume":"86","author":"Fairlamb","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1126\/science.285.5425.242","article-title":"A nucleoside transporter from Trypanosoma brucei involved in drug resistance","volume":"285","author":"Maser","year":"1999","journal-title":"Science"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/EC.2.5.1003-1008.2003","article-title":"Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei","volume":"2","author":"Matovu","year":"2003","journal-title":"Eukaryot. Cell"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Graf, F.E., Ludin, P., Wenzler, T., Kaiser, M., Brun, R., Pyana, P.P., B\u00fcscher, P., de Koning, H.P., Horn, D., and M\u00e4ser, P. (2013). Aquaporin 2 mutations in Trypanosoma brucei gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprol. PLoS Negl. Trop. Dis., 7.","DOI":"10.1371\/journal.pntd.0002475"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijpddr.2015.04.002","article-title":"Chimerization at the AQP2-AQP3 locus is the genetic basis of melarsoprol-pentamidine cross-resistance in clinical Trypanosoma brucei gambiense isolates","volume":"5","author":"Graf","year":"2015","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1046\/j.1365-3156.2001.00710.x","article-title":"Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis","volume":"6","author":"Blum","year":"2001","journal-title":"Trop. Med. Int. Health"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1007\/s00436-002-0766-5","article-title":"Eflornithine for the treatment of human African trypanosomiasis","volume":"90","author":"Burri","year":"2003","journal-title":"Parasitol. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1126\/science.6775372","article-title":"Polyamine metabolism: A potential therapeutic target in trypanosomes","volume":"210","author":"Bacchi","year":"1980","journal-title":"Science"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/1389557023405549","article-title":"Polyamine metabolism as chemotherapeutic target in protozoan parasites","volume":"2","author":"Bacchi","year":"2002","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/clpt.1981.150","article-title":"Kinetics of alpha-difluoromethylornithine: An irreversible inhibitor of ornithine decarboxylase","volume":"30","author":"Haegele","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"LoGiudice, N., Le, L., Abuan, I., Leizorek, Y., and Roberts, S.C. (2018). Alpha-difluoromethylornithine, an irreversible inhibitor of polyamine biosynthesis, as a therapeutic strategy against hyperproliferative and infectious diseases. Med. Sci., 6.","DOI":"10.3390\/medsci6010012"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/j.1471-4159.2008.05706.x","article-title":"The blood\u2013brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain","volume":"107","author":"Sanderson","year":"2008","journal-title":"J. Neurochem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"14529","DOI":"10.1074\/jbc.R500031200","article-title":"Regulation of ornithine decarboxylase","volume":"281","author":"Pegg","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/0140-6736(92)92180-N","article-title":"Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness","volume":"340","author":"Milord","year":"1992","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.pt.2018.08.006","article-title":"The long wait for a new drug for Human African Trypanosomiasis","volume":"34","author":"Baker","year":"2018","journal-title":"Trends Parasitol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Yun, O., Priotto, G., Tong, J., Flevaud, L., and Chappuis, F. (2010). NECT is next: Implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl. Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000720"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: A multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"Priotto","year":"2009","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-019-1051-6","article-title":"Fexinidazole: First global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pt.2017.12.002","article-title":"Fexinidazole: A new drug for African sleeping sickness on the horizon","volume":"34","author":"Pollastri","year":"2018","journal-title":"Trends Parasitol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0140-6736(17)32758-7","article-title":"Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: A pivotal multicentre, randomised, non-inferiority trial","volume":"391","author":"Mesu","year":"2018","journal-title":"Lancet"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.actatropica.2019.105107","article-title":"Drug discovery for Chagas disease: A viewpoint","volume":"198","author":"Kratz","year":"2019","journal-title":"Acta Trop."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijpddr.2019.11.004","article-title":"Current trends in the pharmacological management of Chagas disease","volume":"12","author":"Ribeiro","year":"2019","journal-title":"Int. J. Parasitol. Drugs Drug. Resist."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/17512433.2018.1509704","article-title":"Clinical and pharmacological profile of benznidazole for treatment of Chagas disease","volume":"11","author":"Kratz","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pt.2014.04.003","article-title":"Nitro drugs for the treatment of trypanosomatid diseases: Past, present, and future prospects","volume":"30","author":"Patterson","year":"2014","journal-title":"Trends Parasitol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.2174\/156802611796575894","article-title":"Trypanocidal activity of nitroaromatic prodrugs: Current treatments and future perspectives","volume":"11","author":"Wilkinson","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1080\/14656566.2019.1650915","article-title":"An evaluation of benznidazole as a Chagas disease therapeutic","volume":"20","author":"Caldas","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e01912-16","DOI":"10.1128\/AAC.01912-16","article-title":"Pharmacokinetics of benznidazole in healthy volunteers and implications in future clinical trials","volume":"61","author":"Molina","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Altcheh, J., Moscatelli, G., Mastrantonio, G., Moroni, S., Giglio, N., Marson, M.E., Ballering, G., Bisio, M., Koren, G., and Garc\u00eda-Bournissen, F. (2014). Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0002907"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.actatropica.2017.07.004","article-title":"Prevention of congenital Chagas disease by Benznidazole treatment in reproductive-age women. An observational study","volume":"174","author":"Vigliano","year":"2017","journal-title":"Acta Trop."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.01401-12","article-title":"Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic Chagas disease. Antimicrob","volume":"57","author":"Pinazo","year":"2013","journal-title":"Agents Chemother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actatropica.2015.12.017","article-title":"Current drug therapy and pharmaceutical challenges for Chagas disease","volume":"156","author":"Bermudez","year":"2016","journal-title":"Acta Tropica"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.4269\/ajtmh.16-0761","article-title":"Experimental and clinical treatment of Chagas disease: A review","volume":"97","author":"Sales","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1073\/pnas.0711014105","article-title":"A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes","volume":"105","author":"Wilkinson","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_106","first-page":"671","article-title":"The pharmacokinetics of nifurtimox in chronic renal failure","volume":"42","author":"Thambo","year":"1992","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1191\/0960327106het653oa","article-title":"Toxic side effects of drugs used to treat CD (American trypanosomiasis)","volume":"25","author":"Castro","year":"2006","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1128\/AAC.00246-11","article-title":"Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness","volume":"55","author":"Kaiser","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1021\/acs.jmedchem.5b01699","article-title":"Repositioning antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-activity studies on a preclinical candidate for visceral leishmaniasis","volume":"59","author":"Thompson","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e00048-18","DOI":"10.1128\/CMR.00048-18","article-title":"Recent development of visceral leishmaniasis treatments: Successes, pitfalls, and perspectives","volume":"31","author":"Alves","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1515\/pac-2018-1102","article-title":"Current and promising novel drug candidates against visceral leishmaniasis","volume":"91","author":"Reguera","year":"2019","journal-title":"Pure Appl. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijpddr.2019.06.003","article-title":"Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis","volume":"11","author":"Caridha","year":"2019","journal-title":"Int. J. Parasitol. Drugs Drug. Resist."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.3390\/molecules14072317","article-title":"Pentavalent antimonials: New perspectives for old drugs","volume":"14","author":"Demicheli","year":"2009","journal-title":"Molecules"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e12431","DOI":"10.1111\/pim.12431","article-title":"Expression profiling of Sudanese visceral leishmaniasis patients pre- and post-treatment with sodium stibogluconate","volume":"39","author":"Salih","year":"2017","journal-title":"Parasite Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1074\/jbc.M005423200","article-title":"Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani","volume":"276","author":"Ulrich","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1517\/14656566.2013.755515","article-title":"Leishmaniasis: An update of current pharmacotherapy","volume":"14","author":"Sundar","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/S0140-6736(15)60395-6","article-title":"Arsenic, antimony, and Leishmania: Has arsenic contamination of drinking water in India led to treatment- resistant kala-azar?","volume":"385","author":"Perry","year":"2015","journal-title":"Lancet"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pt.2013.12.004","article-title":"Post kala-azar dermal leishmaniasis: An unresolved mystery","volume":"30","author":"Mukhopadhyay","year":"2014","journal-title":"Trends Parasitol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.3390\/ijerph7124267","article-title":"Antimony toxicity","volume":"7","author":"Sundar","year":"2010","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1517\/14740338.2013.827168","article-title":"Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B","volume":"12","author":"Loo","year":"2013","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1128\/AAC.34.2.183","article-title":"Amphotericin B: Current understanding of mechanisms of action","volume":"34","author":"Brajtburg","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","article-title":"Liposomal Amphotericin B (AmBisome\u00ae): A review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions","volume":"76","author":"Stone","year":"2016","journal-title":"Drugs"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","article-title":"Single-dose liposomal amphotericin B for visceral leishmaniasis in India","volume":"362","author":"Sundar","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/08982104.2017.1380664","article-title":"The care and feeding of a commercial liposomal product: Liposomal amphotericin B (AmBisome\u00ae)","volume":"27","author":"Jensen","year":"2017","journal-title":"J. Liposome Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jac\/49.suppl_1.37","article-title":"Amphotericin B nephrotoxicity","volume":"49","author":"Deray","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJM199912093412403","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"341","author":"Jha","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1128\/AAC.48.8.3010-3015.2004","article-title":"Possible mechanism of miltefosine-mediated death of Leishmania donovani","volume":"48","author":"Verma","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/jac\/dkt262","article-title":"Immunomodulatory effects of antileishmanial drugs","volume":"68","author":"Ghosh","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1017\/S0031182017002116","article-title":"Chemotherapeutics of visceral leishmaniasis: Present and future developments","volume":"145","author":"Sundar","year":"2018","journal-title":"Parasitology"},{"key":"ref_131","first-page":"1530","article-title":"Pharmacokinetics, safety, and efficacy of an allometric miltefosine regimen for the treatment of visceral leishmaniasis in eastern African children: An open-label, phase ii clinical trial","volume":"68","author":"Mbui","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_132","first-page":"733","article-title":"Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management","volume":"3","author":"Sundar","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Jamil, K.M., Haque, R., Rahman, R., Faiz, M.A., Bhuiyan, A.T., Kumar, A., Hassan, S.M., Kelly, H., Dhalaria, P., and Kochhar, S. (2015). Effectiveness study of paromomycin im injection (PMIM) for the treatment of Visceral Leishmaniasis (VL) in Bangladesh. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0004118"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1056\/NEJMoa066536","article-title":"Injectable paromomycin for Visceral leishmaniasis in India","volume":"356","author":"Sundar","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/cid\/cix807","article-title":"Long-term clinical outcomes in visceral leishmaniasis\/human immunodeficiency virus-coinfected patients during and after pentamidine secondary prophylaxis in Ethiopia: A single-arm clinical trial","volume":"66","author":"Diro","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Rahman, R., Goyal, V., Haque, R., Jamil, K., Faiz, A., Samad, R., Ellis, S., Balasegaram, M., Boer, M.D., and Rijal, S. (2017). Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005635"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4269\/ajtmh.2007.77.89","article-title":"Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: A retrospective comparison with 30-day sodium stibogluconate monotherapy","volume":"77","author":"Melaku","year":"2007","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12936-019-2724-z","article-title":"The past, present and future of anti-malarial medicines","volume":"18","author":"Tse","year":"2019","journal-title":"Malar. J."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s11427-015-4948-7","article-title":"The discovery of artemisinin and the Nobel Prize in Physiology or Medicine","volume":"58","author":"Su","year":"2015","journal-title":"Sci. China Life Sci."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/1475-2875-10-263","article-title":"Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration","volume":"10","author":"Morris","year":"2011","journal-title":"Malar. J."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"19383","DOI":"10.1074\/jbc.274.27.19383","article-title":"Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite","volume":"274","author":"Pandey","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0020-7519(02)00194-7","article-title":"Artemisinin: Mechanisms of action, resistance and toxicity","volume":"32","author":"Meshnick","year":"2002","journal-title":"Int. J. Parasitol."},{"key":"ref_143","unstructured":"WHO (2019, November 10). Guidelines for the Treatment of Malaria. Third Edition April. 2015. Available online: https:\/\/www.who.int\/malaria\/publications\/atoz\/9789241549127\/en\/."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"International Artemisinin Study Group (2004). Artesunate combinations for treatment of malaria: Meta-analysis. Lancet, 363, 9\u201317.","DOI":"10.1016\/S0140-6736(03)15162-8"},{"key":"ref_145","first-page":"CD007483","article-title":"Artemisinin-based combination therapy for treating uncomplicated malaria","volume":"8","author":"Sinclair","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000252658","article-title":"Pharmacokinetic and toxicological profile of artemisinin compounds: An update","volume":"84","author":"Medhi","year":"2009","journal-title":"Pharmacology"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1126\/science.271.5246.219","article-title":"Plasmodium hemozoin formation mediated by histidine-rich proteins","volume":"271","author":"Sullivan","year":"1996","journal-title":"Science"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1386207053328101","article-title":"Targeting the hemozoin synthesis pathway for new antimalarial drug discovery: Technologies for in vitro \u03b2-hematin formation assay","volume":"8","author":"Tekwani","year":"2005","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jiph.2014.04.007","article-title":"Shifting from quinine to artesunate as first-line treatment of severe malaria in children and adults: Saving more lives","volume":"7","author":"Noubiap","year":"2014","journal-title":"J. Infect. Public Health"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40265-018-0911-9","article-title":"Drugs in development for malaria","volume":"78","author":"Ashley","year":"2018","journal-title":"Drugs"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2165\/00003088-199019040-00002","article-title":"Clinical pharmacokinetics of mefloquine","volume":"19","author":"Karbwang","year":"1990","journal-title":"Clin. Pharmacokinet."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000109767","article-title":"Antimalarial drug toxicity: A review","volume":"53","author":"Alkadi","year":"2007","journal-title":"Chemotherapy"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2165\/00003495-199345030-00009","article-title":"Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy","volume":"45","author":"Palmer","year":"1993","journal-title":"Drugs"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(96)06217-4","article-title":"Systematic review of amodiaquine treatment in uncomplicated malaria","volume":"348","author":"Olliaro","year":"1996","journal-title":"Lancet"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/pr.115.011411","article-title":"Role of cytochrome P450 2C8 in drug metabolism and interactions","volume":"68","author":"Backman","year":"2015","journal-title":"Pharm. Rev."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.2147\/DDDT.S61443","article-title":"Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: The evidence to date","volume":"10","author":"Ebstie","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1086\/512241","article-title":"Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites","volume":"195","author":"Imwong","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/jtm\/tay110","article-title":"Tafenoquine for travelers\u2019 malaria: Evidence, rationale and recommendations","volume":"25","author":"Baird","year":"2018","journal-title":"J. Travel. Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/20477724.2015.1133033","article-title":"Primaquine treatment and relapse in Plasmodium vivax malaria","volume":"110","author":"Rishikesh","year":"2016","journal-title":"Pathog. Glob. Health"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S1413-8670(10)70084-2","article-title":"Clinical aspects of hemolysis in patients with Plasmodium vivax malaria treated with primaquine, in the Brazilian Amazon","volume":"14","author":"Sardinha","year":"2010","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12936-018-2265-x","article-title":"Efficacy and safety of artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Sudan: A systematic review and meta-analysis","volume":"17","author":"Adam","year":"2018","journal-title":"Malar. J."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.molbiopara.2013.02.008","article-title":"Folate metabolism in human malaria parasites\u201475 years on","volume":"188","author":"Hyde","year":"2013","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00002018-200730060-00003","article-title":"Safety and toxicity of sulfadoxine\/pyrimethamine: Implications for malaria prevention in pregnancy using intermittent preventive treatment","volume":"30","author":"Peters","year":"2007","journal-title":"Drug Saf."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/med.21377","article-title":"Strategies for the optimization of natural leads to anticancer drugs or drug candidates","volume":"36","author":"Xiao","year":"2016","journal-title":"Med. Res. Rev."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1039\/c3np70052f","article-title":"Matching the power of high throughput screening to the chemical diversity of natural products","volume":"30","author":"Henrich","year":"2013","journal-title":"Nat. Prod. Rep."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1021\/acschembio.8b00389","article-title":"NCI Program for natural product discovery: A publicly-accessible library of natural product fractions for high-throughput screening","volume":"13","author":"Thornburg","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/1087057114555846","article-title":"High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: Human African trypanosomiasis, leishmaniasis, and Chagas disease","volume":"20","author":"Annang","year":"2015","journal-title":"J. Biomol. Screen."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijpddr.2014.05.001","article-title":"Target-based vs. phenotypic screenings in Leishmania drug discovery: A marriage of convenience or a dialogue of the deaf?","volume":"4","author":"Reguera","year":"2014","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.1021\/jm400362b","article-title":"Drug discovery for neglected diseases: Molecular target-based and phenotypic approaches","volume":"56","author":"Gilbert","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrd.2017.111","article-title":"Opportunities and challenges in phenotypic drug discovery: An industry perspective","volume":"16","author":"Moffat","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/clpt.2012.236","article-title":"Phenotypic vs. target-based drug discovery for first-in-class medicines","volume":"93","author":"Swinney","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1021\/acs.jcim.7b00072","article-title":"Cheminformatic analysis of antimalarial chemical space illuminates therapeutic mechanisms and offers strategies for therapy development","volume":"57","author":"Varela","year":"2017","journal-title":"J. Chem. Inf. Model."},{"key":"ref_173","first-page":"427","article-title":"Adaptation of High-Throughput Screening in drug discovery\u2014Toxicological screening tests","volume":"13","author":"Markowicz","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.drudis.2017.06.004","article-title":"Leishmaniasis drug discovery: Recent progress and challenges in assay development","volume":"22","author":"Zulfiqar","year":"2017","journal-title":"Drug Discov.Today"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.pt.2007.08.019","article-title":"Target assessment for antiparasitic drug discovery","volume":"23","author":"Frearson","year":"2007","journal-title":"Trends Parasitol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.2174\/1381612823666170601101644","article-title":"Parasite polyamines as pharmaceutical targets","volume":"23","author":"Roberts","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1042\/bst0310411","article-title":"Turnover of trypanosomal ornithine decarboxylases","volume":"31","author":"Persson","year":"2003","journal-title":"Biochem. Soc. Trans."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/B978-0-12-385863-4.00004-6","article-title":"Targeting Trypanosoma cruzi sterol 14\u03b1-demethylase (CYP51). Chagas disease, Part, A","volume":"75","author":"Lepesheva","year":"2011","journal-title":"Adv. Parasitol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ijpddr.2011.12.002","article-title":"Recent developments in sterol 14-demethylase inhibitors for Chagas disease","volume":"2","author":"Bucknera","year":"2012","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas\u2019 disease","volume":"370","author":"Molina","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1473-3099(17)30538-8","article-title":"Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: A proof-of-concept, randomised, placebo-controlled trial","volume":"18","author":"Torrico","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/cmdc.201100344","article-title":"Identification of inhibitors of the Leishmania cdc2-related protein kinase CRK3","volume":"6","author":"Cleghorn","year":"2011","journal-title":"ChemMedChem"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-018-0356-z","article-title":"Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis","volume":"560","author":"Wyllie","year":"2018","journal-title":"Nature"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"7206","DOI":"10.1074\/jbc.M211391200","article-title":"Myristoyl-CoA: Protein N-myristoyltransferase, an essential enzyme and potential drug target in kinetoplastid parasites","volume":"278","author":"Price","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/jm201091t","article-title":"Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors","volume":"55","author":"Brand","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/cmdc.201500301","article-title":"Development of small-molecule Trypanosoma brucei N-myristoyltransferase inhibitors: Discovery and optimisation of a novel binding mode","volume":"10","author":"Spinks","year":"2015","journal-title":"ChemMedChem"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1042\/bse0510063","article-title":"Folate metabolic pathways in Leishmania","volume":"51","author":"Vickers","year":"2011","journal-title":"Essays Biochem."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2958.2008.06305.x","article-title":"Chemical and genetic validation of dihydrofolate reductase-thymidylate synthase as a drug target in African trypanosomes","volume":"69","author":"Sienkiewicz","year":"2008","journal-title":"Mol. Microbiol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/2472555218823171","article-title":"Accelerating drug discovery efforts for trypanosomatidic infections using an integrated transnational academic drug discovery platform","volume":"24","author":"Moraes","year":"2019","journal-title":"SLAS Discov."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.4155\/fmc-2018-0512","article-title":"Targeting pteridine reductase 1 and dihydrofolate reductase: The old is a new trend for leishmaniasis drug discovery","volume":"11","author":"Kagami","year":"2019","journal-title":"Future Med. Chem."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2958.2009.06761.x","article-title":"Dissecting the essentiality of the bifunctional trypanothione synthetase-amidase in Trypanosoma brucei using chemical and genetic methods","volume":"74","author":"Wyllie","year":"2009","journal-title":"Mol. Microbiol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1700373","DOI":"10.1002\/ardp.201700373","article-title":"Molecular insights into trypanothione reductase-inhibitor interaction: A structure-based review","volume":"351","author":"Tiwari","year":"2018","journal-title":"Archiv. Pharm."},{"key":"ref_193","first-page":"939","article-title":"Trypanothione reductase: A target for the development of anti-Trypanosoma cruzi drugs","volume":"17","author":"Paulino","year":"2017","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_194","first-page":"8676578","article-title":"Relevance of trypanothione reductase inhibitors on Trypanosoma cruzi infection: A systematic review, meta-analysis, and in silico integrated approach","volume":"2018","author":"Teixeira","year":"2018","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_195","first-page":"733","article-title":"Targeting atypical trypanosomatid DNA topoisomerase I","volume":"15-16","author":"Redondo","year":"2006","journal-title":"Drug Discov. Today"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.molbiopara.2004.04.006","article-title":"RNA interference of Trypanosoma brucei topoisomerase IB: Both subunits are essential","volume":"136","author":"Bakshi","year":"2004","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1128\/AAC.00499-12","article-title":"Indotecan (LMP400) and AM13-55: Two novel indenoisoquinolines show potential for treating visceral leishmaniasis","volume":"56","author":"Prada","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1087057114550585","article-title":"Chagas disease drug discovery: Toward a new era","volume":"20","author":"Chatelain","year":"2015","journal-title":"J. Biomol. Screen."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijpddr.2012.01.003","article-title":"Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?","volume":"2","author":"Chatelain","year":"2012","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.drudis.2014.09.012","article-title":"Trypanosomatids see the light: Recent advances in bioimaging research","volume":"20","author":"Reguera","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1574-6976.2010.00252.x","article-title":"Noninvasive biophotonic imaging for studies of infectious disease","volume":"35","author":"Andreu","year":"2011","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.pt.2009.07.006","article-title":"Imaging Leishmania development in their host cells","volume":"25","author":"Lang","year":"2009","journal-title":"Trends Parasitol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/1087057116673796","article-title":"Evaluation of parameters impacting drug susceptibility in intracellular Trypanosoma cruzi assay protocols","volume":"22","author":"Yang","year":"2017","journal-title":"SLAS Discov."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.pt.2009.06.006","article-title":"Reporter genes facilitating discovery of drugs targeting protozoan parasites","volume":"25","author":"Dube","year":"2009","journal-title":"Trends Parasitol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.1038\/srep08771","article-title":"New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: An open resource","volume":"5","author":"Manzano","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Calvo-\u00c1lvarez, E., Stamatakis, K., Punz\u00f3n, C., \u00c1lvarez-Velilla, R., Tejer\u00eda, A., Escudero-Mart\u00ednez, J.M., P\u00e9rez-Pertejo, Y., Fresno, M., Bala\u00f1a-Fouce, R., and Reguera, R.M. (2015). Infrared fluorescent imaging as a potent tool for in vitro, ex vivo and in vivo models of visceral leishmaniasis. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003666"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.meegid.2018.01.011","article-title":"A new chimeric triple reporter fusion protein as a tool for in vitro and in vivo multimodal imaging to monitor the development of African trypanosomes and Leishmania parasites","volume":"63","author":"Crouzols","year":"2018","journal-title":"Infect. Genet. Evol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0166-6851(00)00270-X","article-title":"Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models","volume":"110","author":"Roy","year":"2000","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0166-6851(00)00195-X","article-title":"Targeted integration into a rRNA locus results in uniform and high-level expression of transgenes in Leishmania amastigotes","volume":"107","author":"Mottram","year":"2000","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.2144\/03355rr02","article-title":"Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging","volume":"35","author":"Choy","year":"2003","journal-title":"Biotechniques"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1128\/AAC.49.9.3776-3783.2005","article-title":"Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening","volume":"49","author":"Ashutosh","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.parint.2013.07.011","article-title":"In vivo imaging of trypanosomes for a better assessment of host\u2013parasite relationships and drug efficacy","volume":"63","author":"Goyard","year":"2014","journal-title":"Parasitol. Int."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1756-3305-7-89","article-title":"In vivo imaging of mice infected with bioluminescent Trypanosoma cruzi unveils novel sites of infection","volume":"7","author":"Henriques","year":"2014","journal-title":"Parasit. Vectors"},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"\u00c1lvarez-Velilla, R., Guti\u00e9rrez-Corbo, M.C., Punz\u00f3n, C., P\u00e9rez-Pertejo, M.Y., Bala\u00f1a-Fouce, R., Fresno, M., and Reguera, R.M. (2019). A chronic bioluminescent model of experimental visceral leishmaniasis for accelerating drug discovery. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007133"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Giroud, C., Ottones, F., Coustou, V., Dacheux, D., Biteau, N., Miezan, B., Van Reet, N., Carrington, M., Doua, F., and Baltz, T. (2009). Murine models for Trypanosoma brucei gambiense disease progression\u2014From silent to chronic infections and early brain tropism. PLoS Negl. Trop. Dis., 3.","DOI":"10.1371\/journal.pntd.0000509"},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Kessler, R.L., Gradia, D.F., de C\u00e1ssia Pontello Rampazzo, R., Louren\u00e7o, \u00c9.E., Fid\u00eancio, N.J., Manhaes, L., Probst, C.M., \u00c1vila, A.R., and Fragoso, S.P. (2013). Stage-regulated GFP expression in Trypanosoma cruzi: Applications from host-parasite interactions to drug screening. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0067441"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1462-5822.2011.01593.x","article-title":"Quantitative proteome profiling informs on phenotypic traits that adapt Leishmania donovani for axenic and intracellular proliferation","volume":"13","author":"Pescher","year":"2011","journal-title":"Cell. Microbiol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/jac\/dkp206","article-title":"Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening","volume":"64","author":"Singh","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/adt.2015.652","article-title":"High-content assay for measuring intracellular growth of Leishmania in human macrophages","volume":"13","author":"Dagley","year":"2015","journal-title":"Assay Drug Dev. Technol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.drudis.2019.03.007","article-title":"Walking a tightrope: Drug discovery in visceral leishmaniasis","volume":"24","author":"Reguera","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Osorio, Y., Travi, B.L., Renslo, A.R., Peniche, A.G., and Melby, P.C. (2011). Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system. PLoS Negl. Trop. Dis., 5.","DOI":"10.1371\/journal.pntd.0000962"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1128\/AAC.00887-13","article-title":"Development of an ex vivo lymph node explant model for identification of novel molecules active against Leishmania major","volume":"58","author":"Peniche","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_223","doi-asserted-by":"crossref","unstructured":"Ettinger, N.A., and Wilson, M.E. (2008). Macrophage and T-cell gene expression in a model of early infection with the protozoan Leishmania chagasi. PLoS Negl. Trop. Dis., 2.","DOI":"10.1371\/journal.pntd.0000252"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd4683","article-title":"Hit and lead criteria in drug discovery for infectious diseases of the developing world","volume":"14","author":"Katsuno","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrmicro.2016.193","article-title":"Anti-trypanosomatid drug discovery: An ongoing challenge and a continuing need","volume":"15","author":"Field","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.pt.2016.04.014","article-title":"Phenotypic screens in antimalarial drug discovery","volume":"32","author":"Hovlid","year":"2016","journal-title":"Trends Parasitol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrd4457","article-title":"Trial watch: Next-generation antimalarial from phenotypic screen shows clinical promise","volume":"13","author":"Cully","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.chembiol.2012.01.004","article-title":"Global phenotypic screening for antimalarials","volume":"19","author":"Guiguemde","year":"2012","journal-title":"Chem. Biol."},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Linzke, M., Yan, S.L.R., T\u00e1rnok, A., Ulrich, H., Groves, M.R., and Wrenger, C. (2019). Live and let dye: Visualizing the cellular compartments of the malaria parasite Plasmodium falciparum. Cytometry A.","DOI":"10.1002\/cyto.a.23927"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1021\/acsinfecdis.7b00197","article-title":"Fragment-Based Screening of a natural product library against 62 potential malaria drug targets employing native mass spectrometry","volume":"4","author":"Vu","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1021\/cb500981y","article-title":"Yeast-based high-throughput screen identifies Plasmodium falciparum equilibrative nucleoside transporter 1 inhibitors that kill malaria parasites","volume":"10","author":"Frame","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ijpddr.2018.04.007","article-title":"Functional screening of selective mitochondrial inhibitors of Plasmodium","volume":"8","author":"Fuente","year":"2018","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"eaau1682","DOI":"10.1126\/science.aau1682","article-title":"Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target","volume":"365","author":"Alam","year":"2019","journal-title":"Science"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1016\/j.bmc.2006.02.026","article-title":"Antimalarial potential of xestoquinone, a protein kinase inhibitor isolated from a Vanuatu marine sponge Xestospongia sp.","volume":"14","author":"Laurent","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"10053","DOI":"10.1021\/acs.jmedchem.8b01161","article-title":"Target validation and identification of novel boronate inhibitors of the Plasmodium falciparum proteasome","volume":"61","author":"Xie","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.4155\/fmc-2017-0250","article-title":"Plasmodium falciparum dihydroorotate dehydrogenase: A drug target against malaria","volume":"10","author":"Hoelz","year":"2018","journal-title":"Future Med. Chem."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"21847","DOI":"10.1074\/jbc.M501100200","article-title":"High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase","volume":"280","author":"Baldwin","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1473-3099(18)30309-8","article-title":"Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: A proof-of-concept, open-label, phase 2a study","volume":"18","author":"Casapia","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coph.2018.05.006","article-title":"The antimalarial pipeline","volume":"42","author":"Wells","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm.3073","article-title":"Malaria biology and disease pathogenesis: Insights for new treatments","volume":"19","author":"Miller","year":"2013","journal-title":"Nat. Med."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3389\/fphar.2017.00754","article-title":"Development in assay methods for in vitro antimalarial drug efficacy testing: A systematic review","volume":"8","author":"Sinha","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"5982","DOI":"10.1128\/AAC.00709-12","article-title":"In vitro activity of fluorescent dyes against asexual blood stages of Plasmodium falciparum","volume":"56","author":"Joanny","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12936-017-2151-y","article-title":"Unclear association between levels of Plasmodium falciparum lactate dehydrogenase (PfLDH) in saliva of malaria patients and blood parasitaemia: Diagnostic implications?","volume":"17","author":"Nambati","year":"2018","journal-title":"Malar. J."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1475-2875-12-58","article-title":"Evaluation of bioluminescence-based assays of anti-malarial drug activity","volume":"12","author":"Hasenkamp","year":"2013","journal-title":"Malar. J."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acsinfecdis.5b00143","article-title":"High-throughput luciferase-based assay for the discovery of therapeutics that prevent malaria","volume":"2","author":"Swann","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.exppara.2008.05.003","article-title":"Plasmodium falciparum: Development of a transgenic line for screening antimalarials using firefly luciferase as the reporter","volume":"120","author":"Cui","year":"2008","journal-title":"Exp. Parasitol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12936-019-2661-x","article-title":"Updating the modified Thompson test by using whole-body bioluminescence imaging to replace traditional efficacy testing in experimental models of murine malaria","volume":"18","author":"Caridha","year":"2019","journal-title":"Malar. J."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-1-4939-6960-9_9","article-title":"SYBR\u00ae Green I-based fluorescence assay to assess cell viability of malaria parasites for routine use in compound screening","volume":"1601","author":"Leidenberger","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.trstmh.2008.01.021","article-title":"Performance and reliability of the SYBR Green I based assay for the routine monitoring of susceptibility of Plasmodium falciparum clinical isolates","volume":"102","author":"Rason","year":"2008","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1128\/AAC.00527-15","article-title":"Assessment of the worldwide antimalarial resistance network standardized procedure for in vitro malaria drug sensitivity testing using SYBR green assay for field samples with various initial parasitemia levels","volume":"60","author":"Cheruiyot","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1128\/AAC.01370-08","article-title":"Assessment of malaria in vitro drug combination screening and mixed-strain infections using the malaria SYBR green I-based fluorescence assay","volume":"53","author":"Co","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/1475-2875-8-294","article-title":"A comparative study of a flow-cytometry-based assessment of in vitro Plasmodium falciparum drug sensitivity","volume":"8","author":"Karl","year":"2009","journal-title":"Malar. J."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1007\/s00436-017-5477-z","article-title":"Adaptation and optimization of a fluorescence-based assay for in vivo antimalarial drug screening","volume":"116","author":"Arias","year":"2017","journal-title":"Parasitol. Res."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.actatropica.2011.12.010","article-title":"Flow cytometric enumeration of Plasmodium berghei-infected red blood cells stained with SYBR green I","volume":"122","author":"Somsak","year":"2012","journal-title":"Acta Trop."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1128\/AAC.48.5.1807-1810.2004","article-title":"Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy","volume":"48","author":"Bennett","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/adt.2011.0378","article-title":"Validating a firefly luciferase-based high-throughput screening assay for antimalarial drug discovery","volume":"10","author":"Che","year":"2012","journal-title":"Assay Drug Dev. Technol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1128\/AAC.00431-10","article-title":"Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay","volume":"54","author":"Lucumi","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_258","doi-asserted-by":"crossref","unstructured":"Cervantes, S., Prudhomme, J., Carter, D., Gopi, K.G., Li, Q., Chang, Y.T., and Le Roch, K.G. (2009). High-content live cell imaging with RNA probes: Advancements in high-throughput antimalarial drug discovery. BMC Cell Biol., 10.","DOI":"10.1186\/1471-2121-10-45"},{"key":"ref_259","doi-asserted-by":"crossref","unstructured":"Cervantes, S., Stout, P.E., Prudhomme, J., Engel, S., Bruton, M., Cervantes, M., Carter, D., Tae-Chang, Y., Hay, M.E., and Aalbersberg, W. (2012). High content live cell imaging for the discovery of new antimalarial marine natural products. BMC Infect. Dis., 12.","DOI":"10.1186\/1471-2334-12-1"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-4939-7847-2_3","article-title":"Phenotypic screening of small molecules with antimalarial activity for three different parasitic life stages","volume":"1787","author":"Kato","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/med.21486","article-title":"Multistage inhibitors of the malaria parasite: Emerging hope for chemoprotection and malaria eradication","volume":"38","author":"Gupta","year":"2018","journal-title":"Med. Res. Rev."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1128\/AAC.01949-15","article-title":"Luciferase-based, high-throughput assay for screening and profiling transmission-blocking compounds against Plasmodium falciparum gametocytes","volume":"60","author":"Lucantoni","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.pt.2018.07.001","article-title":"Antimalarial transmission-blocking interventions: Past, present, and future","volume":"34","author":"Delves","year":"2018","journal-title":"Trends Parasitol."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1093\/jac\/dkt165","article-title":"A Plasmodium falciparum screening assay for anti-gametocyte drugs based on parasite lactate dehydrogenase detection","volume":"68","author":"Silvestrini","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.molbiopara.2013.02.005","article-title":"A quantitative high throughput assay for identifying gametocytocidal compounds","volume":"188","author":"Tanaka","year":"2013","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/2472555218796410","article-title":"Identification of antimalarial inhibitors using late-stage gametocytes in a phenotypic live\/dead assay","volume":"24","author":"Spicer","year":"2019","journal-title":"SLAS Discov."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1038\/s41467-018-05777-2","article-title":"A high throughput screen for next-generation leads targeting malaria parasite transmission","volume":"9","author":"Delves","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"16414","DOI":"10.1038\/srep16414","article-title":"A simple and predictive phenotypic High Content Imaging assay for Plasmodium falciparum mature gametocytes to identify malaria transmission blocking compounds","volume":"5","author":"Lucantoni","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1128\/AAC.00870-13","article-title":"Identification of MMV malaria box inhibitors of Plasmodium falciparum early-stage gametocytes using a luciferase-based high-throughput assay","volume":"57","author":"Lucantoni","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.chom.2015.12.001","article-title":"High-throughput assay and discovery of small molecules that interrupt malaria transmission","volume":"19","author":"Plouffe","year":"2016","journal-title":"Cell Host Microbe"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/jac\/dkv493","article-title":"A chemical susceptibility profile of the Plasmodium falciparum transmission stages by complementary cell-based gametocyte assays","volume":"71","author":"Camarda","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/infdis\/jir037","article-title":"A high-throughput screen targeting malaria transmission stages opens new avenues for drug development","volume":"203","author":"Buchholz","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.4155\/fmc.12.188","article-title":"Whole-cell in vitro screening for gametocytocidal compounds","volume":"4","author":"Lucantoni","year":"2012","journal-title":"Future Med. Chem."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1128\/AAC.04684-14","article-title":"Imaging-based high-throughput screening assay to identify new molecules with transmission-blocking potential against Plasmodium falciparum female gamete formation","volume":"59","author":"Delves","year":"2015","journal-title":"Antimicrob. Agents Chemother"},{"key":"ref_275","doi-asserted-by":"crossref","unstructured":"Sanders, N.G., Sullivan, D.J., Mlambo, G., Dimopoulos, G., and Tripathi, A.K. (2014). Gametocytocidal screen identifies novel chemical classes with Plasmodium falciparum transmission blocking activity. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0105817"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12936-017-1805-0","article-title":"Novel lead structures with both Plasmodium falciparum gametocytocidal and asexual blood stage activity identified from high throughput compound screening","volume":"16","author":"Sun","year":"2017","journal-title":"Malar. J."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/infdis\/jis184","article-title":"Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug","volume":"205","author":"Martin","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrmicro3097","article-title":"Techniques & applications: A new tool for liver-stage malaria","volume":"11","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1038\/s41467-018-04221-9","article-title":"A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum","volume":"9","author":"Roth","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1179\/2047773215Y.0000000013","article-title":"Killing the hypnozoite\u2014Drug discovery approaches to prevent relapse in Plasmodium vivax","volume":"109","author":"Campo","year":"2015","journal-title":"Pathog. Glob. Health"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/AAC.50.4.1586-1589.2006","article-title":"New approach for high-throughput screening of drug activity on Plasmodium liver stages","volume":"50","author":"Gego","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.chom.2013.06.005","article-title":"A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax","volume":"14","author":"March","year":"2013","journal-title":"Cell Host Microbe"},{"key":"ref_283","doi-asserted-by":"crossref","unstructured":"Chattopadhyay, R., Velmurugan, S., Chakiath, C., Andrews Donkor, L., Milhous, W., Barnwell, J.W., Collins, W.E., and Hoffman, S.L. (2010). Establishment of an in vitro assay for assessing the effects of drugs on the liver stages of Plasmodium vivax malaria. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0014275"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"eaat9446","DOI":"10.1126\/science.aat9446","article-title":"Open-source discovery of chemical leads for next-generation chemoprotective antimalarials","volume":"362","author":"Meister","year":"2018","journal-title":"Science"},{"key":"ref_285","doi-asserted-by":"crossref","unstructured":"Lage, O.M., Ramos, M.C., Calisto, R., Almeida, E., Vasconcelos, V., and Vicente, F. (2018). Current screening methodologies in drug discovery for selected human diseases. Mar. Drugs, 16.","DOI":"10.3390\/md16080279"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bjp.2014.07.001","article-title":"New drugs with antiprotozoal activity from marine algae: A review","volume":"24","author":"Torres","year":"2014","journal-title":"Rev. Bras. Farmacol."},{"key":"ref_287","doi-asserted-by":"crossref","unstructured":"Tchokouaha Yamthe, L.R., Appiah-Opong, R., Tsouh Fokou, P.V., Tsabang, N., Fekam Boyom, F., Nyarko, A.K., and Wilson, M.D. (2017). Marine algae as source of novel antileishmanial drugs: A review. Mar. Drugs, 15.","DOI":"10.3390\/md15110323"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.3390\/md9112369","article-title":"4-Acetoxydolastane diterpene from the Brazilian brown alga Canistrocarpus cervicornis as antileishmanial agent","volume":"9","author":"Britta","year":"2011","journal-title":"Mar. Drugs"},{"key":"ref_289","doi-asserted-by":"crossref","unstructured":"Soares, D.C., Calegari-Silva, T.C., Lopes, U.G., Teixeira, V.L., de Palmer Paix\u00e3o, I.C., Cirne-Santos, C., Bou-Habib, D.C., and Saraiva, E.M. (2012). Dolabelladienetriol, a compound from Dictyota pfaffii algae, inhibits the infection by Leishmania amazonensis. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001787"},{"key":"ref_290","doi-asserted-by":"crossref","unstructured":"Chiboub, O., Sifaoui, I., Lorenzo-Morales, J., Abderrabba, M., Mejri, M., Fern\u00e1ndez, J.J., Pi\u00f1ero, J.E., and D\u00edaz-Marrero, A.R. (2019). Spiralyde A, an antikinetoplastid dolabellane from the brown alga Dictyota spiralis. Mar. Drugs, 17.","DOI":"10.3390\/md17030192"},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3390\/md11030599","article-title":"Eleganolone, a diterpene from the French marine alga Bifurcaria bifurcata inhibits growth of the human pathogens Trypanosoma brucei and Plasmodium falciparum","volume":"11","author":"Attioua","year":"2013","journal-title":"Mar. Drugs"},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exppara.2017.01.002","article-title":"Antileishmanial activity of meroditerpenoids from the macroalgae Cystoseira baccata","volume":"174","author":"Gangadhar","year":"2017","journal-title":"Exp. Parasitol."},{"key":"ref_293","doi-asserted-by":"crossref","unstructured":"Soares, D.C., Szlachta, M.M., Teixeira, V.L., Soares, A.R., and Saraiva, E.M. (2016). The brown alga Stypopodium zonale (Dictyotaceae): A potential source of anti-leishmania drugs. Mar. Drugs, 14.","DOI":"10.3390\/md14090163"},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.phytol.2014.12.019","article-title":"Antileishmanial activity of fucosterol recovered from Lessonia vadosa Searles (Lessoniaceae) by SFE, PSE and CPC","volume":"11","author":"Becerra","year":"2015","journal-title":"Phytochem. Lett."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"103276","DOI":"10.1016\/j.bioorg.2019.103276","article-title":"Antiprotozoal activities of marine polyether triterpenoids","volume":"92","author":"Sifaoui","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.3390\/md8112733","article-title":"Effect of elatol, isolated from red seaweed Laurencia dendroidea, on Leishmania amazonensis","volume":"8","author":"Filho","year":"2010","journal-title":"Mar. Drugs."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1055\/s-0030-1250526","article-title":"Antileishmanial sesquiterpenes from the Brazilian red alga Laurencia dendroidea","volume":"77","author":"Fujii","year":"2011","journal-title":"Planta Med."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/jac\/dkq502","article-title":"Fucoidan cures infection with both antimony-susceptible and -resistant strains of Leishmania donovani through Th1 response and macrophage-derived oxidants","volume":"66","author":"Kar","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4062\/biomolther.2016.067","article-title":"Marine sponges as a drug treasure","volume":"24","author":"Anjum","year":"2016","journal-title":"Biomol. Ther."},{"key":"ref_300","doi-asserted-by":"crossref","unstructured":"Cheng, C., MacIntyre, L., Abdelmohsen, U.R., Horn, H., Polymenakou, P.N., Edrada-Ebel, R., and Hentschel, U. (2015). Biodiversity, anti-trypanosomal activity screening, and metabolomic profiling of actinomycetes isolated from Mediterranean sponges. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0138528"},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.1021\/ja00280a055","article-title":"Manzamine A, a novel antitumor alkaloid from a sponge","volume":"108","author":"Sakai","year":"1986","journal-title":"J. Am. Chem. Soc."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1128\/AAC.44.6.1645-1649.2000","article-title":"In vivo antimalarial activity of the beta-carboline alkaloid manzamine A","volume":"44","author":"Ang","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1021\/jm030475b","article-title":"New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases","volume":"47","author":"Yousaf","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1021\/np800163u","article-title":"Kinetic studies and bioactivity of potential manzamine prodrugs","volume":"71","author":"Shilabin","year":"2008","journal-title":"J. Nat. Prod."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.drudis.2014.06.010","article-title":"Manzamine alkaloids: Isolation, cytotoxicity, antimalarial activity and SAR studies","volume":"19","author":"Ashok","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ejmech.2014.07.006","article-title":"Manzamine alkaloids as antileishmanial agents: A review","volume":"97","author":"Ashok","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_307","doi-asserted-by":"crossref","unstructured":"Shady, N.H., Fouad, M.A., Kamel, M.S., Schirmeister, T., and Abdelmohsen, U.R. (2019). Natural product repertoire of the Genus Amphimedon. Mar. Drugs, 17.","DOI":"10.3390\/md17010019"},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.3390\/md9102131","article-title":"Kinase Inhibitors from marine sponges","volume":"9","author":"Skropeta","year":"2011","journal-title":"Mar. Drugs"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.bbrc.2005.10.121","article-title":"DNA binding properties of 9-substituted harmine derivatives","volume":"338","author":"Cao","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/md7020130","article-title":"Marine antimalarials","volume":"7","author":"Fattorusso","year":"2009","journal-title":"Mar. Drugs"},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1039\/C0OB00326C","article-title":"Anti-malarial, anti-algal, anti-tubercular, anti-bacterial, anti-photosynthetic, and anti-fouling activity of diterpene and diterpene isonitriles from the tropical marine sponge Cymbastela hooperi","volume":"9","author":"Wright","year":"2011","journal-title":"Org. Biomol. Chem."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1021\/jm0010724","article-title":"Inhibition of heme detoxification processes underlies the antimalarial activity of terpene isonitrile compounds from marine sponges","volume":"44","author":"Wright","year":"2001","journal-title":"J. Med. Chem."},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"PB8","DOI":"10.1055\/s-0034-1382374","article-title":"Characterization of membranolides B-H from Dendrilla membranosa and their activity against leishmaniasis","volume":"80","author":"Witowski","year":"2014","journal-title":"Planta Med."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/md8010047","article-title":"Inhibitory activity of marine sponge-derived natural products against parasitic protozoa","volume":"8","author":"Orhan","year":"2010","journal-title":"Mar. Drugs"},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1021\/np100348x","article-title":"Antiprotozoal steroidal saponins from the marine sponge Pandaros acanthifolium","volume":"73","author":"Regalado","year":"2010","journal-title":"J. Nat. Prod."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1099\/00221287-70-3-491","article-title":"Effect of long-chain fatty acids on some trypanosomatid flagellates","volume":"70","author":"Cunningham","year":"1972","journal-title":"J. Gen. Microbiol."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1172\/JCI115678","article-title":"Antimalarial properties of n-3 and n-6 polyunsaturated fatty acids: In vitro effects on Plasmodium falciparum and in vivo effects on P. berghei","volume":"89","author":"Kumaratilake","year":"1992","journal-title":"J. Clin. Invest."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s11745-009-3345-z","article-title":"Total synthesis and antileishmanial activity of the natural occurring acetylenic fatty acids 6-heptadecynoic acid and 6-icosynoic acid","volume":"44","author":"Carballeira","year":"2009","journal-title":"Lipids"},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijpddr.2014.07.006","article-title":"Trypanosomatids topoisomerase re-visited. New structural findings and role in drug discovery","volume":"4","author":"Reguera","year":"2014","journal-title":"Int. J. Parasitol. Drugs Drug. Resist."},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.chemphyslip.2010.11.006","article-title":"First total synthesis and antileishmanial activity of (Z)-16-methyl-11-heptadecenoic acid, a new marine fatty acid from the sponge Dragmaxia undata","volume":"164","author":"Carballeira","year":"2011","journal-title":"Chem. Phys. Lipids"},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1016\/j.tetlet.2010.09.083","article-title":"The first total synthesis of the (\u00b1)-17-methyl-trans-4,5-methyleneoctadecanoic acid and related analogs with antileishmanial activity","volume":"51","author":"Carballeira","year":"2010","journal-title":"Tetrahedron Lett."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1016\/j.bmcl.2012.08.019","article-title":"2-Alkynoic fatty acids inhibit topoisomerase IB from Leishmania donovani","volume":"22","author":"Carballeira","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.chemphyslip.2013.05.002","article-title":"Recent developments in the antiprotozoal and anticancer activities of the 2-alkynoic fatty acids","volume":"172","author":"Carballeira","year":"2013","journal-title":"Chem. Phys. Lipids"},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11745-015-4114-9","article-title":"Novel very long-chain \u03b1-methoxylated \u03b15,9 fatty acids from the sponge Asteropus niger are effective inhibitors of topoisomerases IB","volume":"51","author":"Carballeira","year":"2016","journal-title":"Lipids"},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.3390\/md11103661","article-title":"Synthesis of marine \u03b1-methoxylated fatty acid analogs that effectively inhibit the topoisomerase IB from Leishmania donovani with a mechanism different from that of camptothecin","volume":"11","author":"Carballeira","year":"2013","journal-title":"Mar. Drugs"},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"7475","DOI":"10.1016\/j.bmc.2010.08.055","article-title":"2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections","volume":"18","author":"Tasdemir","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1016\/j.bmcl.2014.07.050","article-title":"2-Octadecynoic acid as a dual life stage inhibitor of Plasmodium infections and plasmodial FAS-II enzymes","volume":"24","author":"Carballeira","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/md18010005","article-title":"Marine pharmacology in 2014\u20132015: Marine compounds with antibacterial, antidiabetic, antifungal, anti-inflammatory, antiprotozoal, antituberculosis, antiviral, and anthelmintic activities; affecting the immune and nervous systems, and other miscellaneous mechanisms of action","volume":"18","author":"Mayer","year":"2019","journal-title":"Mar. Drugs"},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"7869","DOI":"10.3390\/molecules19067869","article-title":"Secondary metabolites from Vietnamese marine invertebrates with activity against Trypanosoma brucei and T. cruzi","volume":"19","author":"Thao","year":"2014","journal-title":"Molecules"},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"12459","DOI":"10.3390\/molecules200712459","article-title":"Anti-protozoal activities of cembrane-type diterpenes from Vietnamese soft corals","volume":"20","author":"Thao","year":"2015","journal-title":"Molecules"},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00436-008-1154-6","article-title":"Antiprotozoan activity of Brazilian marine cnidarian extracts and of a modified steroid from the octocoral Carijoa riisei","volume":"103","author":"Migotto","year":"2008","journal-title":"Parasitol. Res."}],"container-title":["Marine Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-3397\/18\/4\/187\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:13:52Z","timestamp":1760174032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-3397\/18\/4\/187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":331,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["md18040187"],"URL":"https:\/\/doi.org\/10.3390\/md18040187","relation":{},"ISSN":["1660-3397"],"issn-type":[{"value":"1660-3397","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,31]]}}}